dismiss

Pre-Bid now on over 2,500 items! We go LIVE on June 6th, 10AM EDT!

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

European Press Room Homepage

Lake Constance Radiation Oncology Clinic evaluates the IQM System for linear accelerators

Nuffield Health Cheltenham Hospital offers single dose IORT for early breast cancer

University Medical Centre Utrecht treats first cancer patient with Elekta Unity

Compamed 2017: An international platform for the medical technology sector

Blue Earth Diagnostics gets European approval to market Axumin for PET imaging recurrent prostate cancer

UK's first high-energy proton beam therapy system arrives in Wales

First patient treated with IBA pencil beam scanning at the Institute Curie Proton Therapy Center

Gustave Roussy, DOSIsoft collaborate on big data and radiomics for radiation oncology

Nearly 25 percent of patients say mechanical heart valve disturbs sleep

Medica announces the return of its annual App Competition

Study uses Theraclion's ultrasound technology for breast fibroadenoma

Press releases may be edited for formatting or style
MALAKOFF, 8 June 2016 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announced today that Tübingen University has presented promising Echotherapy results from its breast fibroadenoma (BFA) trial. 90% of BFA patients treated with Echotherapy presented at 12 months post-treatment with no vital fibroadenoma tissue.

In the study, 27 patients were treated utilizing Theraclion’s therapeutic ultrasound technology to evaluate the safety and efficacy of the technique. The center’s initial experience was reported in a peer-reviewed article published in the “Senologie Journal”. Now the preliminary histology results were reported by Professor Markus Hahn’s team during the German Congress of Senology in Dresden that took place on May 26—28th, 2016.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



At 12 months post-procedure, biopsies were performed and preliminary results show that:

• 24/27 of the biopsied patients were without residual vital BFA tissue.

• 26 out of 27 patients declared that they would recommend the procedure.

“These results are extremely encouraging,” explains Michel Nuta, Chief Medical Officer of Theraclion. ”Echotherapy has initially been designed for volume reduction of a nodule, not for its complete destruction. These preliminary results show that there is reason to believe that by adapting the protocol, complete tissue destruction can be obtained.”

Pr. Markus Hahn, senior author within the Tubingen group, adds: “Histology performed 12 months after treatment was able to show absence of vital tissue in 90% of cases. The technique which is very easy to use could be envisioned for breast cancer treatment in the short-term future.”

“These results exceed our expectations by far. While for BFA the treatment objective remains volume reduction, complete tissue destruction with a completely non-invasive method without radiation could become a promising option for breast cancer patients in the future”, adds David Caumartin, CEO of Theraclion.

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Back to HCB News
  Pages: 1

European Press Room Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED